MannKind

MannKind Operating Expenses

The Total Operating Expenses of MannKind (MNKD) as of Nov 14, 2026 is 210.48 M USD. In the previous year, Total Operating Expenses was 140.22 M USD — a change of 50.11% (higher).

Operating Expenses

210.48 MUSD

YoY

50.11%

Last updated:

Total Operating Expenses of MannKind is 2025 210.48 M USD. Total Operating Expenses of MannKind was 2024 140.22 M USD. It decreases by 50.11% higher compared to the previous year.

The MannKind Operating Expenses history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Operating Expenses
Date
Operating Expenses
Jan 1, 2018
88.45 M USD
Jan 1, 2019
81.57 M USD
Jan 1, 2020
29.13 M USD
Jan 1, 2021
44.20 M USD
Jan 1, 2022
57.44 M USD
Jan 1, 2023
73.82 M USD
Jan 1, 2024
140.22 M USD
Jan 1, 2025
210.48 M USD
The MannKind Operating Expenses history
YEAROperating ExpensesYoY
210.48 MUSD+50.11%
140.22 MUSD+89.95%
73.82 MUSD+28.52%
57.44 MUSD+29.95%
44.20 MUSD+51.76%
29.13 MUSD-64.29%
81.57 MUSD-7.78%
88.45 MUSD-0.70%
89.08 MUSD+112.13%
41.99 MUSD-69.59%
138.08 MUSD-23.13%
179.63 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

MannKind Stock analysis

What does MannKind do? MannKind Corp is a biopharmaceutical company that specializes in the development, production, and marketing of inhalable medications. The company was founded in 1991 by renowned scientist Alfred E. Mann and is headquartered in Westlake Village, California. MannKind Corp's history began with its founding in 1991 and the development of technologies for manufacturing injectable drugs. Over the years, the company has continuously evolved its technologies and now specializes in inhalable medications. MannKind Corp offers a wide portfolio of products in various areas, with the main areas being diabetes, lung and respiratory diseases, and cancer and immunology. The company develops and produces innovative medications and inhalation devices that allow patients to fight their illnesses. In particular, MannKind Corp has achieved significant success in the field of diabetes treatment. The company has developed an inhalable insulin solution that allows patients to quickly and easily inhale insulin. This novel insulin preparation called Afrezza was launched in the U.S. market in 2015 and greatly improves the treatment of both Type 1 and Type 2 diabetes. With Afrezza, MannKind Corp has achieved a milestone in medical history. In addition to Afrezza, MannKind is also working on other promising projects such as an inhalable drug for COPD (chronic obstructive pulmonary disease), an inhalable painkiller, and a cancer medication. The company also operates its own research department to develop new drugs and therapies. To realize its business model, the company utilizes partnerships and joint ventures to successfully bring its products to market. For example, it has formed a partnership with Sanofi, a globally leading biopharmaceutical company, to launch Afrezza in Europe. It has also established a partnership with Receptor Life Sciences Inc. in the U.S. to develop an inhalable cannabinoid medication for neuropathic pain. MannKind Corp is a company with ambitious goals and visions. It has already made significant advancements in development and elevated the treatment of diseases to a higher level. With its innovative products and technologies, the company remains a leading player in the biopharmaceutical industry and contributes to improving people's lives. MannKind is one of the most popular companies on Eulerpool.

Frequently Asked Questions about MannKind stock

Total Operating Expenses of MannKind is 210.48 M USD in 2025.

Total Operating Expenses of MannKind changed from 140.22 M USD to 210.48 M USD, representing a 50.11% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Total Operating Expenses MannKind since 2006 – with annual values, charts, and detailed analysis.

Operating expenses are the costs incurred in the normal course of business operations, including COGS, SG&A, R&D, and depreciation.

Total Operating Expenses's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Total Operating Expenses's MannKind historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — MannKind

All Key Metrics — MannKind